165 related articles for article (PubMed ID: 32696071)
1. Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer.
Failing JJ; Aubry MC; Mansfield AS
Cancer Immunol Immunother; 2021 Jan; 70(1):215-219. PubMed ID: 32696071
[TBL] [Abstract][Full Text] [Related]
2. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer.
Kikuchi E; Yamazaki K; Torigoe T; Cho Y; Miyamoto M; Oizumi S; Hommura F; Dosaka-Akita H; Nishimura M
Cancer Sci; 2007 Sep; 98(9):1424-30. PubMed ID: 17645781
[TBL] [Abstract][Full Text] [Related]
3. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.
Kudo Y; Haymaker C; Zhang J; Reuben A; Duose DY; Fujimoto J; Roy-Chowdhuri S; Solis Soto LM; Dejima H; Parra ER; Mino B; Abraham R; Ikeda N; Vaporcyan A; Gibbons D; Zhang J; Lang FF; Luthra R; Lee JJ; Moran C; Huse JT; Kadara H; Wistuba II
Ann Oncol; 2019 Sep; 30(9):1521-1530. PubMed ID: 31282941
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
5. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Baba T; Uramoto H; So T; Yamada S
Anticancer Res; 2013 May; 33(5):2123-8. PubMed ID: 23645764
[TBL] [Abstract][Full Text] [Related]
7. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?
Ramnath N; Tan D; Li Q; Hylander BL; Bogner P; Ryes L; Ferrone S
Cancer Immunol Immunother; 2006 Aug; 55(8):891-9. PubMed ID: 16187081
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape.
Song SG; Kim S; Koh J; Yim J; Han B; Kim YA; Jeon YK; Chung DH
Cancer Immunol Immunother; 2021 Jul; 70(7):2035-2048. PubMed ID: 33420630
[TBL] [Abstract][Full Text] [Related]
9. Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.
Sabbatino F; Liguori L; Polcaro G; Salvato I; Caramori G; Salzano FA; Casolaro V; Stellato C; Col JD; Pepe S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023239
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.
Lin A; Zhu CC; Chen HX; Chen BF; Zhang X; Zhang JG; Wang Q; Zhou WJ; Hu W; Yang HH; Xu HH; Yan WH
J Cell Mol Med; 2010 Sep; 14(9):2318-29. PubMed ID: 19602033
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.
Baba T; Shiota H; Kuroda K; Shigematsu Y; Ichiki Y; Uramoto H; Hanagiri T; Tanaka F
Int J Clin Oncol; 2013 Dec; 18(6):997-1004. PubMed ID: 23124547
[TBL] [Abstract][Full Text] [Related]
12. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
16. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
Talebian Yazdi M; van Riet S; van Schadewijk A; Fiocco M; van Hall T; Taube C; Hiemstra PS; van der Burg SH
Oncotarget; 2016 Jan; 7(3):3477-88. PubMed ID: 26658106
[TBL] [Abstract][Full Text] [Related]
17. The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer.
He XP; Song FJ; Liu XY; Wang Z; Li XX; Liu FY; Chen G; Jiang WP
J Int Med Res; 2013 Oct; 41(5):1473-83. PubMed ID: 23975858
[TBL] [Abstract][Full Text] [Related]
18. Involvement of HLA class I molecules in the immune escape of urologic tumors.
Carretero R; Gil-Julio H; Vázquez-Alonso F; Garrido F; Castiñeiras J; Cózar JM
Actas Urol Esp; 2014 Apr; 38(3):192-9. PubMed ID: 24315763
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
20. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
